contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


senzime-secures-tetragraph-installations-across-all-sites-of-world-leading-us-hospital-system

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Senzime operates in the medical technology industry and focuses on the development and manufacture of systems for monitoring and diagnostics in healthcare. The portfolio includes systems used to automate and measure the substances glucose and lactate in blood and tissues. The company's products are aimed at healthcare institutions and physicians. The operations are global. Senzime was founded in 1999 and is headquartered in Uppsala, Sweden.

Senzime

Uppsala, Sweden – Aug 5, 2025 – Senzime today announced another strategic milestone in the U.S., having secured the delivery of its TetraGraph system to all hospital sites within one of the ...

<div class="mfn-preamble"><p><strong>Uppsala, Sweden – Aug 5, 2025 – Senzime today announced another strategic milestone in the U.S., having secured the delivery of its TetraGraph system to all hospital sites within one of the world’s top-ranked hospital systems. Following a successful evaluation, the next-generation TetraGraph will be implemented for monitoring both pediatric and adult patients during surgery, including those undergoing robotic procedures. With this latest expansion, total annual patient volumes across the system are expected to reach approximately 15,000.</strong></p></div><div class="mfn-body"><p>“Successes like this demonstrate the market’s ongoing shift toward full alignment with clinical guidelines, while also establishing strong reference accounts that reinforce the value of our solutions and the unique services we offer to enhance patient safety and standardize neuromuscular monitoring,” said Philip Siberg, CEO of Senzime. “The TetraGraph system is the result of over 40 years of scientific research, refined in collaboration with leading clinicians worldwide. Our monitoring algorithms continuously improve as we gather more data, and no other solution offers the proprietary capabilities we provide to ensure full compliance with clinical standards.”</p><p>Senzime’s TetraGraph system is used by anesthesiologists in thousands of operating rooms at leading hospitals globally. Its proprietary technology meets the requirements of recently published U.S. and European guidelines recommending neuromuscular monitoring for all patients receiving paralytic drugs. TetraGraph helps clinicians accurately determine appropriate dosing of neuromuscular blocking agents and their antagonists, while also supporting safe recovery post-surgery.</p></div><div class="mfn-footer mfn-contacts mfn-8e21f6378646"><p><strong class="mfn-heading-1">For further information, please contact:</strong></p><hr><p>Philip Siberg, CEO of Senzime AB<br>Phone: +46 (0) 707 90 67 34, e-mail:&nbsp;<a rel="noopener" href="mailto:philip.siberg@senzime.com">philip.siberg@senzime.com</a></p></div><div class="mfn-footer mfn-about mfn-51570c1d0876"><p><strong class="mfn-heading-1">About Senzime</strong></p><hr><p>Senzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery.<br><br>Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at <a rel="noopener" href="https://senzime.com/">senzime.com</a>.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/c3789327-dbf2-41c1-bb1d-c25abe173848/senzime-secures-tetragraph-installations-across-all-sites-of-world-leading-us-hospital-system.pdf" class="mfn-generated mfn-primary">Senzime Secures TetraGraph Installations Across All Sites of World-Leading US Hospital System</a></p></div>

Senzime Secures TetraGraph Installations Across All Sites of World-Leading US Hospital System